SG11201504447XA - Novel pharmaceutical formulations and their use in the treatment of periodontal disease - Google Patents

Novel pharmaceutical formulations and their use in the treatment of periodontal disease

Info

Publication number
SG11201504447XA
SG11201504447XA SG11201504447XA SG11201504447XA SG11201504447XA SG 11201504447X A SG11201504447X A SG 11201504447XA SG 11201504447X A SG11201504447X A SG 11201504447XA SG 11201504447X A SG11201504447X A SG 11201504447XA SG 11201504447X A SG11201504447X A SG 11201504447XA
Authority
SG
Singapore
Prior art keywords
treatment
pharmaceutical formulations
periodontal disease
novel pharmaceutical
novel
Prior art date
Application number
SG11201504447XA
Other languages
English (en)
Inventor
Thomas Kissel
Ching Pong Mak
Original Assignee
Perioc Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Perioc Ltd filed Critical Perioc Ltd
Publication of SG11201504447XA publication Critical patent/SG11201504447XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0063—Periodont
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11201504447XA 2012-12-13 2013-12-13 Novel pharmaceutical formulations and their use in the treatment of periodontal disease SG11201504447XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1222455.6A GB201222455D0 (en) 2012-12-13 2012-12-13 Novel pharmaceutical formulations and their use in the treatment of periodontaldisease
PCT/GB2013/053283 WO2014091239A1 (en) 2012-12-13 2013-12-13 Novel pharmaceutical formulations and their use in the treatment of periodontal disease

Publications (1)

Publication Number Publication Date
SG11201504447XA true SG11201504447XA (en) 2015-07-30

Family

ID=47630648

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201504447XA SG11201504447XA (en) 2012-12-13 2013-12-13 Novel pharmaceutical formulations and their use in the treatment of periodontal disease
SG10201704712QA SG10201704712QA (en) 2012-12-13 2013-12-13 Novel pharmaceutical formulations and their use in the treatment of periodontal disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201704712QA SG10201704712QA (en) 2012-12-13 2013-12-13 Novel pharmaceutical formulations and their use in the treatment of periodontal disease

Country Status (11)

Country Link
US (2) US10471058B2 (ja)
EP (2) EP2931299B1 (ja)
JP (2) JP6441809B2 (ja)
KR (1) KR20150095795A (ja)
CN (1) CN104884075B (ja)
CA (1) CA2893935C (ja)
DK (1) DK2931299T3 (ja)
ES (1) ES2718499T3 (ja)
GB (2) GB201222455D0 (ja)
SG (2) SG11201504447XA (ja)
WO (1) WO2014091239A1 (ja)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9890198B2 (en) 2010-12-03 2018-02-13 S&T Global Inc. Cyclosporin derivatives and uses thereof
GB201410869D0 (en) * 2014-06-18 2014-07-30 Perioc Ltd Novel pharmaceutical formulations and their use in the treatment of periodontal disease
EP3773418A2 (en) * 2018-03-27 2021-02-17 DENTSPLY SIRONA Inc. Methods of treatment of the dental pulp and filling root canals using anti inflammatory rinse solution and filling composition
WO2020037530A1 (en) 2018-08-22 2020-02-27 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Crystalline form of compound and uses thereof in medicine
JP7123264B2 (ja) * 2018-12-14 2022-08-22 中美華世通生物医薬科技（武漢）股▲ふん▼有限公司 Ｓｃｙ－６３５のマレイン酸塩、及び医学におけるその使用
AU2021240762A1 (en) * 2020-03-26 2022-10-06 Farsight Medical Technology (Shanghai) Co., Ltd. Cyclophilin inhibitors and uses thereof
CN116323764A (zh) 2020-09-30 2023-06-23 大金工业株式会社 三维造型用组合物和三维造型物
KR102640323B1 (ko) * 2021-11-30 2024-02-27 대우제약 주식회사 사이클로스포린의 안정한 나노 현탁액

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0597697A (ja) * 1991-10-02 1993-04-20 Lion Corp 歯槽骨再生剤
EP0708646A1 (en) * 1994-05-06 1996-05-01 Alcon Laboratories, Inc. Use of vitamin e tocopheryl derivatives in ophthalmic compositions
HU215966B (hu) * 1994-11-21 1999-07-28 BIOGAL Gyógyszergyár Rt. Orálisan alkalmazható, ciklosporint tartalmazó, összetett emulzió-előkoncentrátum
US5565188A (en) * 1995-02-24 1996-10-15 Nanosystems L.L.C. Polyalkylene block copolymers as surface modifiers for nanoparticles
SE9601421D0 (sv) * 1996-04-12 1996-04-12 Astra Ab New composition
US5891845A (en) * 1997-11-21 1999-04-06 Fuisz Technologies Ltd. Drug delivery systems utilizing liquid crystal structures
DE19932157A1 (de) * 1999-07-13 2001-01-18 Pharmasol Gmbh Verfahren zur schonenden Herstellung von hochfeinen Mikropartikeln und Nanopartikeln
PL206018B1 (pl) * 2001-10-19 2010-06-30 Isotechnika Inc Preparat farmaceutyczny, sposób jego wytwarzania, mikroemulsja i zastosowanie tego preparatu farmaceutycznego
PT1436322E (pt) * 2001-10-19 2008-10-23 Isotechnika Inc Misturas de análogos da ciclosporina e sua utilização como agentes imunomodulantes
US20040115287A1 (en) * 2002-12-17 2004-06-17 Lipocine, Inc. Hydrophobic active agent compositions and methods
EP1510206A1 (en) * 2003-08-29 2005-03-02 Novagali Pharma SA Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs
AU2005209201B2 (en) * 2004-01-20 2010-06-03 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
US20050277584A1 (en) * 2004-06-09 2005-12-15 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
CN101048137A (zh) * 2004-10-29 2007-10-03 诺瓦提斯公司 可自发分散的药物组合物
CA2598204C (en) * 2004-11-09 2015-01-13 Board Of Regents, The University Of Texas System Stabilized hme composition with small drug particles
CA2603084A1 (en) * 2005-04-12 2006-10-19 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising cyclosporine
WO2007045027A1 (en) * 2005-10-19 2007-04-26 Chavah Pty Ltd Reduction of side effects from aromatase inhibitors used for treating breast cancer
AU2006311577B2 (en) * 2005-11-09 2013-02-07 Zalicus Inc. Methods, compositions, and kits for the treatment of medical conditions
US10137083B2 (en) * 2006-03-07 2018-11-27 SGN Nanopharma Inc Ophthalmic preparations
CN101032620B (zh) * 2007-03-08 2010-05-19 上海凯昭医药科技有限公司 一种环孢素自乳化制剂及其制备方法
WO2009083155A1 (de) * 2007-12-21 2009-07-09 Holger Essiger Mittel, mit mindestens einem wirkstoff, der eine zahnfleischwachstumswirkung aufweist
WO2010052559A1 (en) * 2008-11-06 2010-05-14 Debio Recherche Pharmaceutique S.A. Cycloundecadepsipeptide compounds and use of said compounds as a medicament
KR100924236B1 (ko) * 2009-06-23 2009-10-29 충남대학교산학협력단 균일한 입도분포를 가지는 초미세입자의 신규한 제조방법 및 장치
CN102085295B (zh) * 2009-12-08 2012-09-05 华中科技大学 口腔粘膜给药的小葱提取物纳米乳药物组合物及其制法
IT1404931B1 (it) * 2010-06-11 2013-12-09 Medivis S R L Composizioni oftalmiche per la somministrazione di principi attivi liposolubili .
CA2814192A1 (en) * 2010-10-12 2012-04-19 Allergan, Inc. Cyclosporin analogs
UA113627C2 (xx) * 2011-05-27 2017-02-27 Кристалічна форма циклоспорину a, фармацевтична композиція та спосіб лікування

Also Published As

Publication number Publication date
JP6441809B2 (ja) 2018-12-19
JP6608028B2 (ja) 2019-11-20
ES2718499T3 (es) 2019-07-02
GB2523707A (en) 2015-09-02
CA2893935C (en) 2021-11-02
CA2893935A1 (en) 2014-06-19
GB201511770D0 (en) 2015-08-19
JP2016504314A (ja) 2016-02-12
KR20150095795A (ko) 2015-08-21
US10471058B2 (en) 2019-11-12
GB201222455D0 (en) 2013-01-30
EP2931299B1 (en) 2019-02-06
JP2019048860A (ja) 2019-03-28
DK2931299T3 (en) 2019-04-23
WO2014091239A1 (en) 2014-06-19
CN104884075B (zh) 2018-04-03
US20200085825A1 (en) 2020-03-19
EP2931299A1 (en) 2015-10-21
EP3498290A1 (en) 2019-06-19
US20150313959A1 (en) 2015-11-05
SG10201704712QA (en) 2017-07-28
CN104884075A (zh) 2015-09-02

Similar Documents

Publication Publication Date Title
HRP20181364T8 (hr) Aminotriazolopiridin, namijenjen upotrebi u liječenju upale, te njegovi farmacetski pripravci
IL231536A (en) Indazole-3-carboxamides, pharmaceuticals containing them and their use in the treatment of diseases
HK1209100A1 (en) N-substituted benzamides and their use in the treatment of pain n-
PL2928484T3 (pl) Związki przydatne w leczeniu lub pielęgnacji skóry, włosów lub błon śluzowych oraz ich kompozycji kosmetycznych lub farmaceutycznych
IL236221A (en) History of theophyridone and pharmacological preparations containing them for the treatment of diseases
IL237369A0 (en) Methods for treating Alzheimer's disease and pharmaceutical compositions thereof
SG11201504447XA (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
IL232256A0 (en) Purine derivatives and their use in the treatment of diseases
HK1199401A1 (en) Pharmaceutical formulations and the use thereof for the treatment of peanut allergy
IL271352B (en) A pharmaceutical preparation containing a derivative of glutarimide and its use in the treatment of eosinophilic diseases
HK1199712A1 (en) 18-methyl-6,7-methylene-3-oxo-17-pregn-4-ene-21,17-carbolactones, pharmaceutical preparations comprising said compounds and use thereof in the treatment of endometriosis 18--67--3--17--4--2117-
HK1203947A1 (en) Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions (halofuginol)
GB2515439B (en) Vesicular formulations for use in the treatment of reduced mobility
IL233875A (en) Preparation and use for the treatment of anal fissures
ZA201402452B (en) Novel pyrimethanil formulations and uses thereof in the treatment of crops
GB2515440B (en) Vesicular Formulations for use in the treatment of Rosacea
IL234093A0 (en) Preparations and dosages for oral administration and their uses for the treatment of Gaucher's disease
HK1214771A1 (zh) 用於治療皮膚病的製劑
HK1206598A1 (en) Eprotirome for use in the prevention and or treatment of hair disorders and compositions thereof
GB201410869D0 (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
ME02285B (me) Farmaceutska jedinjenja koja sadrže beta galaktozidazu i alfa galaktozidazu i njihova upotreba za lečenje bolesti gastroezofagealnog refluksa